DURECT Corporation Announces Fourth Quarter and Year End 2007 Financi...(f POSIDUR has produced supplies fo...)

POSIDUR, has produced supplies for Phase III clinical trials.

POSIDUR is our post-operative pain relief depot that utilizes our

patented SABER(TM) technology to deliver bupivacaine to provide up to

three days of pain relief after surgery. POSIDUR is licensed to Nycomed

for commercialization in Europe and select other countries, and DURECT

has retained commercialization rights in the US, Canada and Asia.

-- ELADUR (TRANSDUR(TM)-Bupivacaine). In December, we announced positive

results from a 60 patient Phase IIa clinical trial. In this study of

patients suffering from post-herpetic neuralgia, ELADUR showed improved

pain control versus placebo during the 3-day continuous treatment

period. In addition, ELADUR appeared to be well tolerated overall, and

patients treated with ELADUR and placebo exhibited similar safety

profiles. We have in place a relationship with Corium International,

whereby Corium will be our worldwide supplier of ELADUR patches.

ELADUR is our proprietary transdermal patch intended to provide

bupivacaine for a period of up to three days from a single application.

We retain full commercial rights to this drug candidate.

-- TRANSDUR-Sufentanil. Endo Pharmaceuticals, our licensee for

commercialization in the US and Canada, has publicly disclosed that

they have commenced their Phase II program in June 2007.

TRANSDUR-Sufentanil is our proprietary transdermal patch intended to

provide sufentanil to chronic pain sufferers for a period of up to

seven days from a single application.

-- Expansion of Patent Portfolio. In the fourth quarter of 2007, we

acquired from a third party a portfolio of worldwide patents relating

to drug delivery technologies. This portfolio consists of

approximately 22 issued and pending U.S. pa
'/>"/>